Patents by Inventor Gestur Vidarsson

Gestur Vidarsson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150323525
    Abstract: The invention relates to means and methods for detecting a cell surface molecule in a cell sample. The invention further relates to a method for blood group typing and screening and to SPR sensors and SPR measuring systems suitable for use in such methods. The method includes steps of allowing a liquid cell sample to flow to and along the sensor surface, temporarily reducing the shear rate of the liquid sample to allow cells in the sample to sediment by binding to a binding compound immobilised on a metal film on the sensor surface, and removing unbound cells or non-specifically bound cells or fragments thereof. Moreover, the ratio of the magnitude of the specific total signal response to the signal response during sedimentation is determined.
    Type: Application
    Filed: December 19, 2013
    Publication date: November 12, 2015
    Inventors: Gestur Vidarsson, Richard Bernardus Maria Schasfoort
  • Patent number: 8426141
    Abstract: The present invention relates to methods for increasing the therapeutic efficacy of immunoglobulin G class 3 (IgG3) antibodies, immunoglobulin G class 3 (IgG3) antibodies with an improved therapeutic efficacy and the use thereof as a medicament, in particularly a medicament for immunotherapy. Specifically, the present invention relates to methods for increasing the therapeutic efficacy of an immunoglobulin G class 3 (IgG3) antibody comprising providing a mutated immunoglobulin G class 3 (IgG3) antibody, wherein the mutation, as compared to the parent immunoglobulin G class 3 (IgG3) antibody, comprises a replacement of the amino acid arginine (R) at position 435 in the CH3 domain with the amino acid histidine (H), and antibodies obtained by the present methods and their use as a medicament.
    Type: Grant
    Filed: January 18, 2008
    Date of Patent: April 23, 2013
    Assignee: Stichting Sanquin Bloedvoorziening
    Inventors: Gestur Vidarsson, Catherine E. Van der Schoot
  • Publication number: 20110003336
    Abstract: The present invention relates to methods for increasing the therapeutic efficacy of immunoglobulin G class 3 (IgG3) antibodies, immunoglobulin G class 3 (IgG3) antibodies with an improved therapeutic efficacy and the use thereof as a medicament, in particularly a medicament for immunotherapy. Specifically, the present invention relates to methods for increasing the therapeutic efficacy of an immunoglobulin G class 3 (IgG3) antibody comprising providing a mutated immunoglobulin G class 3 (IgG3) antibody, wherein the mutation, as compared to the parent immunoglobulin G class 3 (IgG3) antibody, comprises a replacement of the amino acid arginine (R) at position 435 in the CH3 domain with the amino acid histidine (H), and antibodies obtained by the present methods and their use as a medicament.
    Type: Application
    Filed: January 18, 2008
    Publication date: January 6, 2011
    Inventors: Gestur Vidarsson, Catherine E. Van der Schoot
  • Publication number: 20090258008
    Abstract: The invention relates to the field of biochemistry and molecular biology. More specifically the invention relates to the production of (monoclonal) antibodies and even more specifically to the production of therapeutic and diagnostic antibodies. The invention provides a method for producing an antibody or a functional part, derivative and/or analogue thereof in a cell, comprising providing a cell that is capable of producing said antibody with FcRn receptor protein and culturing said cell to allow for production of said antibody.
    Type: Application
    Filed: November 23, 2006
    Publication date: October 15, 2009
    Applicant: UMC UTRECHT HOLDING B.V.
    Inventor: Gestur Vidarsson
  • Publication number: 20050191290
    Abstract: Immunoglobulin light chains (Ig-LC) are produced in excess in animals compared to heavy chains. The present invention implicates Ig-LC in hypersensitivity responses and provides ways for manipulating the responses. The invention further provides a common gamma chain-independent receptor on mast cells capable of mediating the mentioned effects of Ig-LC. In response to activation of the pathway of which the found receptor is a part, a mast cell is activated and stimulated to degranulate.
    Type: Application
    Filed: September 7, 2004
    Publication date: September 1, 2005
    Inventors: Franciscus Nijkamp, Franciscus Antonius Redegeld, Aletta Kraneveld, Johannes Gerardus van de Winkel, Gestur Vidarsson